Stifel Nicolaus reiterated their buy rating on shares of Cara Therapeutics, Inc. (NASDAQ:CARA) in a report issued on Friday, June 30th, MarketBeat Ratings reports. Stifel Nicolaus currently has a $20.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $24.00.
CARA has been the topic of a number of other reports. Raymond James Financial, Inc. reaffirmed a market perform rating and set a $30.00 price objective on shares of Cara Therapeutics in a research report on Friday, April 28th. Piper Jaffray Companies reaffirmed an overweight rating and set a $23.00 price objective on shares of Cara Therapeutics in a research report on Friday, March 3rd. HC Wainwright boosted their price target on Cara Therapeutics from $22.00 to $30.00 and gave the stock a buy rating in a report on Tuesday, March 28th. Zacks Investment Research cut Cara Therapeutics from a hold rating to a sell rating in a report on Tuesday, March 14th. Finally, Vetr raised Cara Therapeutics from a hold rating to a buy rating and set a $18.44 price target on the stock in a report on Wednesday, April 5th. Four analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of Buy and an average target price of $25.68.
Cara Therapeutics (NASDAQ:CARA) traded up 0.72% during trading on Friday, reaching $14.04. 900,908 shares of the company’s stock traded hands. The stock’s market cap is $456.40 million. The company’s 50 day moving average is $17.21 and its 200-day moving average is $16.21. Cara Therapeutics has a 52-week low of $4.97 and a 52-week high of $28.50.
Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.73) by $0.08. The business had revenue of $0.91 million during the quarter, compared to analyst estimates of $0.11 million. During the same period in the prior year, the company posted ($0.39) EPS. The firm’s revenue for the quarter was up 12900.0% on a year-over-year basis. On average, analysts anticipate that Cara Therapeutics will post ($2.44) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Stifel Nicolaus Reiterates Buy Rating for Cara Therapeutics, Inc. (CARA)” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2017/07/28/cara-therapeutics-inc-cara-given-buy-rating-at-stifel-nicolaus-updated-updated-updated.html.
In related news, VP Frederique Ph.D. Menzaghi sold 3,000 shares of the company’s stock in a transaction on Friday, July 14th. The stock was sold at an average price of $15.00, for a total transaction of $45,000.00. Following the completion of the sale, the vice president now directly owns 120,000 shares in the company, valued at approximately $1,800,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Dean Slagel sold 250,000 shares of the company’s stock in a transaction on Thursday, June 29th. The stock was sold at an average price of $25.87, for a total value of $6,467,500.00. The disclosure for this sale can be found here. Insiders sold a total of 278,000 shares of company stock valued at $6,888,750 over the last quarter. Company insiders own 7.70% of the company’s stock.
Several large investors have recently modified their holdings of CARA. Driehaus Capital Management LLC bought a new stake in shares of Cara Therapeutics during the first quarter worth $750,000. Tudor Investment Corp ET AL acquired a new stake in Cara Therapeutics during the first quarter worth approximately $1,354,000. Metropolitan Life Insurance Co. NY acquired a new stake in Cara Therapeutics during the first quarter worth approximately $305,000. Two Sigma Securities LLC acquired a new stake in Cara Therapeutics during the first quarter worth approximately $252,000. Finally, Schwab Charles Investment Management Inc. boosted its stake in Cara Therapeutics by 43.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 39,617 shares of the biopharmaceutical company’s stock worth $729,000 after buying an additional 12,000 shares during the period. Hedge funds and other institutional investors own 53.01% of the company’s stock.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
Receive News & Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.